Lupride Depot 45mg Injection contains Leuprolide, a synthetic nonapeptide analog of gonadotropin-releasing hormone (GnRH). It acts as a potent GnRH agonist, initially stimulating and subsequently downregulating pituitary gonadotropin secretion, leading to decreased production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This results in reduced gonadal steroidogenesis, effectively lowering testosterone and estrogen levels. Lupride Depot 45mg is indicated for the treatment of hormone-responsive conditions such as prostate cancer, endometriosis, uterine fibroids, and central precocious puberty. The depot formulation allows for sustained release of Leuprolide over an extended period, ensuring prolonged therapeutic effect with a single administration. It is administered via intramuscular injection, typically once every 1 to 3 months depending on clinical indication and patient response. Common adverse effects include hot flashes, injection site reactions, decreased libido, and potential bone density reduction with long-term use. Caution is advised in patients with cardiovascular disease or osteoporosis. Monitoring of hormone levels and clinical response is essential to optimize treatment outcomes. Lupride Depot 45mg Injection should be used under specialist supervision, with individualized dosing and careful consideration of contraindications and potential drug interactions.